October 27 & 28, 2020
Sylvio Bengio manages the Scientific programs at Adebiotech, independent Biotechnology think tank. Sylvio holds a PhD in cellular and molecular bioology and has been active in industry through various management positions in Biotechnology and technology supply.
He is a member of the scientific/programming Committee of CFIB2020 Conference and is the main contact for questions related to the scientific agenda.
Deputy head of Biologics Research Dpt. Vitry, Head of Protein Science & Technology, Sanofi, France
32 years experience in Pharma R&D
Head of Protein Science & Technology and Deputy Head Biologics Research Vitry,Sanofi
Between 2012 and 2014 global Head of Protein Biotherapeutics. Previously Head of Protein Production during 12 years in Aventis and Sanofi-Aventis (2000 –2012). Group Leader in Biotechnology, Hoechst Marion Roussel, 1988 –2000, (12 years). PhD in 1988 in Cellular and Molecular Biology (University Paris VI, France): Purification, biochemical and immunological characterization of human teeth collagenase, in Protein Chemistry Lab Institut Pasteur of Paris.
Main expertises in R&D on expression and purification/characterization/developability of recombinant proteins and antibodies, Biologics, for Medicinal Chemistry and Biotherapeutics projects for all kind of uses (screening, crystallography, IHC, PK-PD, in vitro and in vivo studies…). Purification of proteins, from mg scale to several grams (DSP). Support to Medicinal Chemistry projects, and development of purification processes for Biologics. Metalloproteinases. Previously project leader of Cardiovascular and Anti-Infective projects.
Manuel Gea is co-founder & CEO Bio-Modeling Systems: The world’s first Mechanisms-based Medicine company
He is Chairman of the Independent trans-discipline biotech Think Tank Adebiotech, and the co-founder and Chairman of Centrale-Santé, the French Health Think-Tank gathering 2500 members, professional involved in sector innovations and creating value for patients.
Manuel Gea is a serial entrepreneur & business angel developing disruptive innovations (technologies, novel therapies & business models) in the life sciences, IT, digital, healthcare & cosmetics sectors to propose disruptive integrated solutions adapted to each segment..
He spent 30 years creating value in various domains and executive jobs:
- from consumer goods Industry to cosmetics, biotechnology & pharma companies and,
- from business to R&D at Colgate-Palmolive, McKinsey, Boehringer Ingelheim, HemispherX Biopharma, Pherecydes-Pharma, BMSystems and,
- co-founding or contributing to professional organizations (Leem biotech, Medef, Medicen cluster) and Think-Tanks (Adebiotech, Centrale-Santé) to promote disruptive innovation and entrepreneurship.
He is graduated from Ecole Centrale Paris, and has a sociology of organizations degree from Paris IX Dauphine University.
Manuel Gea, is co-founder, CEO & VP R&D IT of BMSystems, The Mechanisms-Based Medicine Company dedicated to the discovery of cost-effective new therapeutic, diagnostic & preventive solutions.
CADI™ Discovery is, since 2004, the first and only to date operational “Mechanisms-based Medicine” platform, that addresses two of the major life sciences issues:
– the complexity of life’s mechanisms with its “Architectural Principle”,
– the significant unreliability of scientific and clinical publications through its “Negative Selection Principle”.
Denis MARCHAND, holder of a PhD in Engineer Science, has more than 13 years of experience in public and private research and development (IRSN, CEA, DTF, University of Tours, INSERM, TTO-SATT Grand Centre). He has worked on multidisciplinary technology transfer projects requiring public / private partnerships. Sensitive to the difficulties encountered by researchers in promoting their project, as well as industrialists to collaborate with the academic world, Denis joined the Cluster Polepharma team in February 2018 with the aim of promoting innovation in the world of health and more particularly biopharmaceuticals and bioproduction by creating bridges between scientists and manufacturers around innovative collaborative projects.
After an agricultural engineer School in France (Lasalle Beauvais), Alexis RANNOU joined ARD for activities in R&D to extract non digestible sugar for surfactant application (1991-1995). He was after in charge of ARD’s pilot plant (1995-1997).
In 1997 he joined the Soliance company (daughter company of ARD) as technical director.
In 2000 he was named as Deputy General Manager in charge of the industrial production.
In 2007 he was in charge of the innovation team and several global accounts.
In 2014 he joined Givaudan as Operations Director & site manager
Since 2018, he held the position of Head of Operations Strategy in charge of tolling & process development for Givaudan Active Beauty
Simon Trancart is co-founder and CEO of Altar. He earned diplomas from Ecole Centrale Paris (France) and Escola Politécnica da Universidade de São Paulo (Brazil). Previously, Simon held different position at the sugar and bioenergies division of engineering group Fives. In 2013, Simon launched Heurisko, a biotech specialized in microbial fluidics. He co-founded Altar in 2017 that supports strain development in several industrial fields.
Geneticist by training, Gilles Truan joined the CNRS in 1997. His research topic was aimed at understanding enzyme structure function relationships through directed evolution techniques with a special focus on cytochrome P450. He then moved towards understanding the role of protein dynamics in their catalytic function, especially the P450redox partners. In 2011, the team joined the Toulouse Biotech Institute in Toulouse and took a new turn towards synthetic biology. Gilles Truan is now the PI of the Molecular and Metabolic Engineering team (I2M) and Head of the Metabolic Engineering Department. The I2M team is widely recognized in France in the field of synthetic biology. Several projects are now ongoing in this field, leading to the synthesis, by yeast, of several important industrial molecules. Gilles Truan is also the director, with Jean-Loup Faulon, of the National Research Group on Synthetic and Systems Biology (BioSynSys).